Loading
Latest filing published 26 Aug 2026 for Estrella Immunopharma, Inc., €70k.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
Filings by Cheng Liu span 2 companies, the busiest being JW (Cayman) Therapeutics Co. Ltd - B and Estrella Immunopharma, Inc. In total, 6 filings cover trades dated from 17 November 2021 to 25 August 2026.
The open-market record consists of 5 sales worth €1.9M, with no purchase. The amount is not disclosed for 2 filings. Outside the open market, there are 1 option exercise.
Most recently, on 26 August 2026, the filings show an option exercise worth €70k in Estrella Immunopharma, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. For comparison, the SEC allows two business days to file a Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
1 of 1 declaration